Free Newsletter
Swine flu offers a new lift to booming vax business
With virtually round-the-clock swine flu news on cable these days, all sorts of news organizations are taking a crack at analyzing the business side of the pandemic equation.
ABC News concludes that whatever else H1N1 means, it's been good for the vaccine industry. The network news program starts with the $1.5 billion spent on the 250 million doses of vaccine purchased from five big manufacturers for the U.S. market. Then there's $10 billion lawmakers budgeted for viral research, tracking the spread of H1N1 and educating the public on the need to get vaccinated. Even doctors and pharmacies seem to be getting a boost from the influx of new business.
One other beneficiary: Vaccine critics and advocates. Trust for America's Health, for example, gets into the ABC spotlight with its projection that a severe pandemic would depress the GDP in the U.S. by five percent, or $683 billion. "We're not seeing a pandemic that's this severe," says Jeff Levi, director of the nonprofit group. "We've dodged a lot of bullets."
- check out the ABC story
Related Articles:
Glaxo sees huge rush for Pandemrix supplies
Manufacturers get green light to start packing flu vax
Pandemic offers AstraZeneca a blockbuster return
Calls for $8B vax campaign grow in U.S.
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




